
GW Pharmaceuticals Plc's (GWP.L) cannabis-derived medicine Sativex has been approved in Britain for treating spasticity in patients with multiple sclerosis, in a landmark decision for the small drugmaker.
The much-delayed product was finally granted a British licence on Thursday, an official from the Medicines and Healthcare products Regulatory Agency (MHRA) told Reuters on Friday.
The company later issued a statement confirming the move.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1814